TARE vs TACE prolongs time to progression in HCC but not overall survivalSeptember 19, 2022Hepatocellular Carcinoma
Baseline DCP levels and NLR predict survival in patients receiving atezolizumab+bevacizumab for advanced HCCSeptember 19, 2022Hepatocellular Carcinoma
First-line lenvatinib+toripalimab+FOLFOX-HAIC shows promise in high-risk advanced HCCSeptember 19, 2022Hepatocellular Carcinoma
HCC: Averting post-TARE hepatic decompensation with careful patient selection September 19, 2022Hepatocellular Carcinoma
Postoperative adjuvant TACE efficacy in HCC depends on micronecrosis stateSeptember 19, 2022Hepatocellular Carcinoma
Unresectable HCC: Atezolizumab+bevacizumab more effective in patients with good liver functionSeptember 19, 2022Hepatocellular Carcinoma
Advanced HCC with macroscopic PVTT: Hepatectomy offers better survival than sorafenibSeptember 19, 2022Hepatocellular Carcinoma
Transradial vs transfemoral access for TACE improves patient satisfaction in HCCSeptember 19, 2022Hepatocellular Carcinoma
CP-A to CP-B progression after lenvatinib initiation in HCC should not halt therapySeptember 19, 2022Hepatocellular Carcinoma
Sintilimab plus IBI305: A promising treatment option for advanced HCCSeptember 19, 2022Hepatocellular Carcinoma
Commentary: Appropriate Downstaging and TACE in HCC, September 2022August 23, 2022Hepatocellular Carcinoma
Repeating TACE yields a survival benefit in intermediate-stage HCCAugust 22, 2022Hepatocellular Carcinoma
Advanced HCC with PVTT: Sorafenib+TACE more efficacious when combined with an immune checkpoint inhibitor and radiotherapyAugust 22, 2022Hepatocellular Carcinoma
HCC: Effective local tumor control with “no-touch” radiofrequency ablationAugust 22, 2022Hepatocellular Carcinoma
Better survival among children vs adults with HCC likely attributed to more aggressive surgical managementAugust 22, 2022Hepatocellular Carcinoma
